In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Amoxicillin Pulsys NDA plans

This article was originally published in Pharmaceutical Approvals Monthly

Executive Summary

Advancis anticipates a second-half 2005 NDA filing for its amoxicillin Pulsys formulation, using the firm's once-a-day pulsatile delivery technology. A Phase III trial in adolescents and adults with acute pharyngitis and/or tonsillitis due to Group A streptococcal infections began dosing Oct. 15, with results expected in the first half of 2005. GlaxoSmithKline terminated development of an Augmentin Pulsys formulation, effective Dec. 15. "Advancis remains confident that pulsatile amoxicillin/clavulanate is technically and commercially viable, and will be exploring other avenues and partners. Additionally, the company believes continued progress on its pulsatile version of amoxicillin will help support future productive Pulsys collaborations," Advancis says...

You may also be interested in...

Par/Advancis Pulsatile Amoxicillin Filing Plans On Hold After Phase III Failure

A potential NDA submission for Advancis' Pulsys pulsatile amoxicillin formulation will be delayed at least until late 2006 following failure of a Phase III trial to show statistical non-inferiority to penicillin

Executives On The Move: Eisai Taps Celgene And Sanofi VPs For Its Team, And Freeline Selects A CEO

Japanese big pharma Eisai taps Celgene and Sanofi execs as its new VPs for corporate affairs and market access. And Freeline Therapeutics, developer of gene therapies for bleeding disorders, selects a former Alnylam Pharma SVP as CEO.

Triptan Switches Offer Hope For Australia’s OTC Market

Switch expert Natalie Gauld says recent triptan switch recommendations signal a turnaround for Australia's OTC market.





Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts